miR-124在胶质瘤组织中的表达及临床意义  

Expression and clinical significance of miR-124 in tissues of gliomas

作　　者：廖银花[1] 邓石军 胡玉林[1] 

机构地区：[1]郴州市第一人民医院病理诊断中心,河南郴州423000 [2]郴州市第四人民医院儿科,河南郴州423000

出　　处：《中国卫生产业》2014年第6期10-11,共2页China Health Industry

摘　　要：目的本文旨在探讨miR-124在胶质瘤组织中的表达及临床意义。方法收集2010年8月—2013年5月胶质瘤患者手术切除标本45例,脑外伤或尸检脑组织共12例作为正常对照,运用原位杂交技术检测胶质瘤组织及正常脑组织中miR-124的表达水平,分析其与胶质瘤临床参数的关系。结果原位杂交检测显示,在45例胶质瘤组织中miR-124阳性表达率为28.9%(13/45例),对照组阳性表达率为75.0%(9/12例),差异有统计学意义,并且miR-124的表达随着胶质瘤患者临床分期进展而降低。结论 miR-124可能成为胶质瘤患者病情进展预测的潜在生物学标志。Objetive To investigate the expression and chnical significance of miR-124 in glioma tissues. Methods 45 glioma tis- sue specimens and 12 brain samples from trauma or autopsy were collected from Aug 2010 to May 2013. Hybridization in situ was performed to test the expression of miR-124. Results The positive expression rate of miR-124 was 28.9% in glioma tissues and 75.0% in normal brain tissues. The downregulation of miR-124 expression was associated with the progression of clinical stage. Conclusion MiR-124 could be regarded as a potential biomarker in predicting the progression in glioma.

关 键 词：MIRNA miR-124 胶质瘤 临床意义 

分 类 号：R739.4[医药卫生—肿瘤]